Marianne Ellen Pavel, Chris Verslype, Pedro Rocha, Alastair Greystoke, Aman Chauhan, Julia Koevi, Martha Mueller, Eric Song, Valeria Lifke, Emily K. Bergsland. "Obrixtamig (BI 764532) in patients (pts) with relapsed/refractory delta-like ligand 3 (DLL3)-high expressing extrapulmonary neuroendocrine carcinoma (epNEC): Dose expansion part of the phase II DAREON-5 trial.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.7_suppl.tps2